Evidence map›Paper›PMID 40707221›Full record

ArticleInternal medicine (Tokyo, Japan)2026

Successful Treatment of Aplastic Anemia Induced by Immune Checkpoint Inhibitors for Lung Cancer.

Chihiro Sumi, Masayo Yamamoto, Rena Sasaki, Takuya Funayama, Takeshi Saito, Mayumi Hatayama, Motohiro Shindo, Yasuhiro Umekage, Takaaki Sasaki, Sayaka Yuzawa and 2 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chihiro SumiDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Japan.
Masayo YamamotoDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Japan.
Rena SasakiDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Japan.
Takuya FunayamaDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Japan.
Takeshi SaitoDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Japan.
Mayumi HatayamaDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Japan.
Motohiro ShindoDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Japan.
Yasuhiro UmekageInfection Control Department, Asahikawa Medical University Hospital, Japan.
Takaaki SasakiDivision of Respiratory Medicine and Neurology, Department of Internal Medicine, Asahikawa Medical University, Japan.
Sayaka YuzawaDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Japan.
Mishie TaninoDepartment of Diagnostic Pathology, Asahikawa Medical University Hospital, Japan.
Shuichiro TakahashiDivision of Hematology, Department of Internal Medicine, Asahikawa Medical University, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immune checkpoint inhibitors (ICIs) are effective against many types of cancers. However, these drugs can trigger unintended immune attacks on normal tissues, leading to a range of side effects known as immune-related adverse events (irAEs). Involvement of the hematopoietic system in irAEs is rare, and a standard treatment has not yet been established. We herein report a 72-year-old man with non-small-cell lung cancer who developed aplastic anemia (AA) after ICI treatment. Eltrombopag improved the long-term blood count without causing severe infection. This case suggests that eltrombopag may be a viable treatment option for ICI-induced AA.

Indexed as

Anemia, AplasticBenzoatesCarcinoma, Non-Small-Cell LungHydrazinesImmune Checkpoint InhibitorsLung NeoplasmsPyrazolesAgedHumansMaleTreatment OutcomeBenzoateseltrombopagHydrazinesImmune Checkpoint InhibitorsPyrazolesaplastic anemiaeltrombopagimmune checkpoint inhibitorsimmune-related adverse events

Identifiers

PMID40707221
PMCPMC12979780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.